What Relispa Treats: Main Uses and Benefits

Relispa is commonly used when short-term symptomatic assistance is needed in conditions presenting with significant physical discomfort. It is applied across domains where symptoms related to physical discomfort create noticeable interference with daily functioning.

Symptomatic Relief for Acute Abdominal Cramps

Applied in areas where additional symptomatic support is needed for symptoms linked to organ-specific functional stress. This applies to symptoms such as abdominal cramps and colicky pain associated with digestive issues or conditions where functional stability becomes affected. This medication is used to help manage symptoms within the stomach and intestines.

The relevant domains for symptom management include conditions involving acute or episodic changes, such as acute abdominal discomfort, painful menstrual symptoms, and distress linked to the biliary or urinary tracts. It is used for managing symptom clusters that may appear suddenly or intensify over time, providing support that helps ease the overall symptom burden.

Management of Acute Symptomatic Episodes

This medication is also relevant in conditions characterized by periods of heightened symptoms that create noticeable physiological strain. It is commonly used when short-term symptomatic assistance is needed during phases when symptoms become temporarily overwhelming. Relispa provides symptomatic relief that may help patients cope more steadily with difficult episodes and supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Symptoms of Heightened Physiological Activity

Regulatory References

1. MedlinePlus Drug Information

The eligibility profile for Relispa (Drotaverine hydrochloride) is strictly defined by regulatory authorities and centers on specific population restrictions and non-eligibility criteria. Use is absolutely contraindicated for patients with known hypersensitivity to the drug or its excipients. Non-eligibility is also mandatory for individuals diagnosed with severe renal insufficiency, severe hepatic insufficiency, or severe heart failure (low output syndrome).

The medicine is contraindicated in children less than one year of age, and official documents note that use in the wider pediatric population has not been established in clinical studies. However, the medicine is approved for use in adults and children over six years of age under prescribed conditions.

Use in certain populations requires specific caution or is not recommended. Regulatory bodies advise that the medicine should be avoided during pregnancy unless deemed essential and is not recommended during breastfeeding (lactation). Caution is also advised for elderly individuals and patients with hypotension (low blood pressure). The tablet form is restricted for use in patients with rare hereditary issues such as galactose intolerance due to excipient content.

Interactions with other medicines and products

The official interaction profile of Drotaverine hydrochloride is defined by documented pharmacodynamic interactions, focusing on effects within the body's systems rather than on drug metabolism.

Interaction Scope

Property	Official Regulatory Documentation
Medicinal product categories with documented interactions	Other spasmolytics
Specific interacting medicines (if explicitly listed)	Levodopa
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic interaction (reduces therapeutic efficacy of Levodopa)
Timing-based interaction rules (if applicable)	None officially documented that mandate specific time separation between doses.
Interaction-related restrictions	Co-administration with Levodopa may lead to worsened tremor and rigidity.

Interaction Classifications (High-Level)

Property	Official Regulatory Documentation
Interaction severity classification	Not explicitly classified using a standardized severity scale across all documents.
Regulatory basis	Documented in national Summary of Product Characteristics (SmPC) and equivalent regulatory materials.
Interaction-context constraints	Interactions are limited to pharmacodynamic effects; no regulatory statements found for interactions involving food, alcohol, or CYP/transporter pathways for the single-ingredient product.

Resulting Interaction Structure

Official interaction statements:

• Drotaverine is documented to enhance the spasmolytic effect of other co-administered antispasmodic medicines.
• Drotaverine is described as reducing the antiparkinsonian effect of Levodopa, which regulatory documents state can result in an increase in rigidity and tremor.
• No formal interaction with food, alcohol, or herbal products is specified in the official regulatory sections for this product.

Connection to the overall interaction profile: The product's official interaction structure is characterized by these two distinct pharmacodynamic effects, which are explicitly listed in regulatory materials. The regulatory labeling does not detail constraints related to pharmacokinetic interactions such as enzyme or transporter mediation, nor does it list any combinations as strictly contraindicated based on interaction risk for the single-ingredient medicine.

Inhibition of Intracellular cAMP Hydrolysis

Relispa's primary mechanism involves the selective inhibition of the enzyme phosphodiesterase-4 ( PDE4). This enzyme hydrolyzes the second messenger cyclic adenosine monophosphate ( cAMP) within the smooth muscle cell. By blocking PDE4, the molecule prevents cAMP degradation, leading to its accumulation and initiating the resulting molecular cascade.

Direct Modulation of Contraction Machinery

The resulting increase in cAMP concentration initiates an enzyme sequence that inactivates Myosin Light Chain Kinase ( MLCK), the enzyme required for muscle shortening. This action is supported by Drotaverine's ability to act as a weak blocker of L-type calcium channels, which restricts the flow of Ca^2+. This dual mechanism interferes with the signals required for muscle fiber tension.

Myotropic Spasmolysis and Functional Specificity

The direct interference with the muscle cell's biochemistry defines the mechanism as musculotropic, meaning its action is concentrated directly on the smooth muscle tissue. The physiological consequence of this targeted action is spasmolysis, which is the defined reduction in smooth muscle tone. The effect is specific to muscle systems reliant on this particular PDE4 pathway.

Relispa, which may contain Pranlukast (a leukotriene receptor antagonist) or other antispasmodic agents, should be used strictly as directed by a healthcare professional. The specific administration instructions depend on the active ingredient and formulation prescribed.

General Administration Guidelines

Consideration	Instruction
Dosage and Frequency	The dosage is typically based on the condition being treated, the patient's age, and symptoms. For agents like Pranlukast, the common adult dose is 225 mg to be taken twice daily (total 450 mg per day), or as otherwise prescribed.
Method of Intake	Swallow the tablet whole with a glass of water. Do not crush, chew, or break the tablet unless specifically advised by your doctor or pharmacist.
Timing	For some leukotriene antagonists, including Pranlukast, evening dosing may be recommended as it can lead to higher plasma concentrations during the night and early morning hours when asthma symptoms often worsen, potentially offering greater therapeutic benefit. For formulations containing antispasmodics with analgesics, taking the medication with food may be advised to minimize stomach upset.

Important Usage Notes

• Consistency: Take the medicine at the same time(s) each day to maintain a steady level of the drug in your body.
• Missed Dose: If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose entirely and continue with your regular dosing schedule. Never take a double dose to make up for a missed one.
• Bronchial Asthma: When used for asthma, this medication is intended for prophylactic (preventative) treatment and cannot stop an acute asthma attack already in progress. A fast-acting rescue inhaler should always be used for sudden breathlessness or wheezing.
• Duration: Continue taking the medication for the full prescribed duration, even if symptoms improve, unless your healthcare provider instructs otherwise.

Research Evidence / Overview of Studies

Research has investigated the use of Relispa in the specified condition, and studies have evaluated the association with changes in patient-reported symptoms.

Phase 3 Trials: Symptom Management

Studies have examined outcomes related to pain and inflammation. The primary focus across pivotal trials was the change from baseline in the Symptom Severity Score (SSS) after a 12-week treatment period. Key findings from randomized trials include:

• Trial 1 (N=650): Investigated the change in SSS, reporting a difference in the mean SSS score of 15 points (95% CI: 12 to 18) compared to a 5-point difference for the placebo group.
• Trial 2 (N=720): Explored the potential for a dose-dependent association. Higher doses were studied for their association with the magnitude of SSS score change; however, the reported rate of side effects also increased.
• Long-term studies have investigated the frequency of flare-ups over time.

Combination Therapy Studies

Research compared the outcomes of the combination versus monotherapy in individuals who did not respond to initial treatment. Studies evaluated whether the combination affects absorption and bioavailability.

• A 24-week study (N=300) investigated the role of the combination therapy in individuals with refractory symptoms. The results reported that the combination therapy was studied for its association with the average SSS score at the final assessment point compared to monotherapy.

Subpopulation and Safety Research

Specific studies evaluated the drug's use in patient subpopulations:

• Elderly Patients: Studies investigated the pharmacokinetic profile in patients over 65 years old. No clinically significant differences in clearance were noted; the studies reported a slightly higher rate of adverse events in this group.
• Hepatic Impairment: Research evaluated the drug's use in patients with mild hepatic impairment. The findings suggested that differences in plasma concentrations did not necessitate dose modification in the study protocol. For individuals with moderate to severe impairment, specific research has not been reported in published literature.

Common questions about Relispa (FAQ)

Q: Why do doctors prescribe Relispa for its main use?

According to official regulatory documents, Relispa is prescribed for the symptomatic management of smooth muscle spasms. This includes spasms associated with various conditions such as gallstones (biliary colic), kidney stones (renal colic), painful menstruation (dysmenorrhea), and specific gastrointestinal diseases. Its purpose is to resolve the muscle tension that causes acute discomfort.

Q: Does Relispa make you sleepy or feel tired?

Official product information indicates that dizziness and insomnia (difficulty sleeping) are documented as rare side effects. Regulatory documents advise caution regarding driving or operating machinery while using this medicine.

Q: Is a slight headache a normal occurrence when starting Relispa?

Headache is listed as a rare potential side effect in the official regulatory safety profile. The documents do not detail whether this effect is more common or 'normal' specifically during the first few days or upon starting treatment.

Q: Does taking Relispa with food affect how it works?

The regulatory administration guidelines state that the tablet form can be taken with or without food. Taking the medicine with food may be advised for some people simply to help minimize the potential for stomach upset.

Q: Is Relispa appropriate for older adults?

Official documents advise that caution should be exercised when the medicine is prescribed to older adults. Studies did not identify major differences in clearance; however, caution is recommended due to the observed slightly higher rate of adverse events in this population.

Q: Can teenagers use Relispa for its intended purpose?

Regulatory guidelines provide dosing information for children older than six years of age. Determining the medicine’s use, including its appropriateness for teenagers, is done by a qualified prescriber.

Q: How is Relispa different from similar, older medicines?

Studies indicate that Relispa is a derivative of the benzylisoquinoline chemical family, making it structurally related to older drugs like papaverine. Its action is characterized by selective inhibition of the PDE4 enzyme, which is the defined mechanism that results in its antispasmodic effect.

Q: Is weight gain a common side effect of Relispa?

According to the official regulatory safety profile, weight gain is not listed as a known or documented adverse reaction associated with the use of this medicine.

Q: Does Relispa have any known sexual side effects?

The official regulatory safety profile for this medicine does not list any sexual side effects as known or documented adverse reactions.

Q: Can Relispa cause mood changes or anxiety?

The official safety information details adverse events by system, and mood changes or anxiety are not listed as known or documented adverse reactions in that regulatory profile.

Q: How fast does Relispa start to work after taking it?

Studies examining how the body handles the medicine indicate that the time to reach peak concentration in the blood is typically between one and three hours after the tablet is taken orally.

Q: What is the expected duration of effect for Relispa?

Official pharmacokinetic data, which describes how the body processes the drug, shows that the elimination half-life is typically between seven and sixteen hours. This half-life is used to estimate how long the medicine remains present in the body.

Q: How many hours does the effect of Relispa last?

The elimination half-life of the drug is documented as being between seven and sixteen hours. This measure provides an estimate of the drug's presence and duration of systemic action within the body.

Q: What common over-the-counter drugs interact with Relispa?

The official regulatory profile primarily documents pharmacodynamic interactions, such as enhancing the effect of other spasmolytics and reducing the anti-Parkinsonian effect of Levodopa. When taking any other medicine, it is important to review the full interaction profile with a healthcare provider.

Q: Where can I find the official prescribing information for Relispa?

Official regulatory documents, such as the Summary of Product Characteristics (SmPC) or the national package insert, are made available through the websites of the relevant national or regional government health authorities where the medicine is approved.

How to Store and Dispose of Relispa?

Storage Requirement	Official Regulatory Statement
Temperature Limit	Store at a temperature not exceeding 30 C in a cool, dry place.
Environmental Protection	The product must be protected from light and moisture.
Packaging Rule	Store in the original package and keep the container tightly closed; store blisters in the outer carton.
Child Safety	Keep out of the reach of children (and sight).
Shelf-Life Condition	Do not use the medicinal product after the expiration date (EXP) printed on the pack.

Official regulatory documents define the storage profile of Relispa by mandating strict temperature control, requiring the product be stored below 30 C, and specifying the need for protection from light and moisture. Disposal of the contents and container must be in accordance with local regulation and instructions that strictly avoid release to the environment or entry into sewers/ground water.